Canagliflozin: 8 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where canagliflozin met resistance it was usually narrowed rather than refused: 6 of 7 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The file has been open for more than a decade: 12.2 years separate the first record, 12 Dec 2013 at AWMSG (Wales), from the most recent, 25 Feb 2026 at NICE (England).
AOTMIT (Poland) changed its position: not recommended on 2 Apr 2021, restricted by 4 Dec 2023, after a resubmission.
No assessment is on file from HAS (France), PBAC (Australia) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for canagliflozin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 2 of 13 records date from 2023 or later.
6 distinct indication wordings are recorded for canagliflozin by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess canagliflozin, on 12 Dec 2013; AOTMIT (Poland) did not open a file until 2 Apr 2021 — a wide spread of 7.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 12 dated records fall in 2014 alone.
Restriction is doing real work here: 6 of 7 decisive outcomes narrowed canagliflozin to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and SMC (Scotland) among others.
4 of the 8 agencies here assessed canagliflozin more than once, AWMSG (Wales) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for canagliflozin.
The full ledger for canagliflozin reads 6 restricted, 2 deferred to NICE, 1 terminated and 1 not recommended, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 4 Dec 2023 | Invokana reimbursement recommendation | recommended conditionally | source |
| PHARMAC (New Zealand) | 19 Mar 2019 | Diabetes - type 2 | PTAC advice: No Formal Recommendation · decision reached | source |
| AWMSG (Wales) | 16 Jul 2015 | In adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as monotherapy when diet an… | superseded (non-submission) | source |
| ZIN (Netherlands) | 4 Nov 2014 | GVS-advies canagliflozine (Invokana®) bij de behandeling van volwassen patiënten met diabetes mellitus type 2 (DM2) - ui… | conditions amended (GVS) | source |
| G-BA (Germany) | 4 Sep 2014 | Invokana — benefit assessment §35a | added benefit: not proven | source |
8 further decisions for canagliflozin, across 6 agencies, are not shown here. They include the most recent record on file, 25 Feb 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- dapagliflozin — divergent outcome (restricted vs recommended) on a shared indication
- saxagliptin — divergent outcome (restricted vs recommended) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
- liraglutide — same ATC class A10B — Diabetes
Coverage: 13 decisions for canagliflozin from 8 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.